Absci: Unlocking the Power of Generative AI to Create Better Drugs for Patients
NASDAQ: ABSI | Absci Website
Absci Corporation is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster.
Absci’s Integrated Drug Creation platform unlocks the potential to shorten preclinical development timelines and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, Absci can screen billions of cells per week, allowing them to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s vision is to deliver breakthrough therapeutics at the click of a button, for everyone.
Absci, a Corporate Marketing Partner of IDG, has released its latest Quarterly Corporate Update video featuring Founder, CEO & Director Sean McClain. Sean discusses how the company is unlocking the power of generative AI to create better drugs for patients.
Absci is a Corporate Marketing Partner of IDG. IDG’s Corporate Marketing Programs are for world-class growth companies interested in driving awareness within high value alternative capital channels including family offices. Throughout the year-long program, IDG sets the stage for you to share your story with in-person presentations, video interviews, virtual events, and a comprehensive marketing program.
To learn more about IDG’s Corporate Marketing Program, please reach out.